Dr. Michael Ropacki is a clinical neuroscientist specializing in neurological disorders, specifically neurodegenerative diseases. Michael is Senior Vice President of Research and Development at MedAvante, an innovator in the collection, management, and analysis of clinical trial data.
A member of the Critical Path Institute’s Coalition Against Major Disease’s digital Drug Development Tool Team, he was previously Co-Chair of the CAMD Preclinical Cognitive Outcome Assessment Team, working with the Food and Drug Administration’s Drug Development Tool, and an Assistant Clinical Professor of Neurology at the Loma Linda University School of Medicine. He serves as Co-Chair of a Scientific Advisory Group for the Innovative Medicines Initiative-Early Proof Of Concept/ Early Prevention of AD program. Michael is also a National Institute of Health advisor to the National Institute on Aging, National Institute of Neurologic Disorders and Stroke, and the Eunice Kennedy Shriver National Institute of Child Health and Human Development.
Recipient of numerous awards, Michael was honored with the 2014 Coalition Against Major Diseases Annual Recognition Award for leadership and dedication in advancing drug development for neurodegenerative diseases. He’s been an author of more than 70 manuscripts, abstract, and presentations, and is an ad hoc reviewer for Clinical Neuropsychologist and the Archives of Clinical Neuropsychology. A 1991 MCC graduate, he holds a bachelor’s degree Summa Cum Laude from the University of Arizona, and a master’s degree and doctorate in Clinical Psychology from Texas Tech University.